Changes in Hong Kong stocks | Yiming Onko-B (01541) rose more than 5% IMM0306 treatment SLE latest data released, SRI-4 response rate reached 90.9%

The Zhitong Finance App learned that the stock price of Yiming Onko-B (01541) was higher. As of press release, it had risen 5.29% to HK$2.885, with a turnover of HK$2,383,700.

According to the news, Yiming Angke announced today that the company will announce the latest results of the phase IB/II study of the CD47×CD20 bispecific fusion protein amurefurop α (IMM0306/IMC-002) in the treatment of severely active SLE in the 2026 annual meeting of the American Society of Rheumatology in the form of a poster. In this phase Ib data analysis, three dose groups of 0.8, 1.2, and 1.6 mg/kg were included, for a total of 33 patients.

IMM0306 has observed encouraging efficacy in patients with SLE. At week 24, SRI-4 response rates for the 0.8, 1.2, and 1.6 mg/kg dose groups were 71.4%, 72.7%, and 90.9%, respectively. At week 52, SRI-4 response rates were 66.7%, 75.0%, and 100%, respectively, showing long-lasting efficacy. Furthermore, pharmacodynamics showed that after receiving the first four doses, peripheral blood CD19+ B cells were cleared to a deep depletion level of <5 cells/μL.